Supernus Pharmaceuticals | SUPN - Interest Expense On Debt


Supernus Pharmaceuticals reported $910K in Interest Expense on Debt for its fiscal quarter ending in June of 2023.





Interest Expense On Debt Change Date
Abbott USD 297M 2M Sep/2026
ANI Pharmaceuticals USD 3.64M 775K Jun/2026
Aurora Cannabis CAD 230K 1.88M Mar/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Canopy Growth CAD 12.31M 4.97M Mar/2026
Cara Therapeutics -89.64M 128.67M Dec/2025
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Eisai JPY 1.96B 409M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Novo Nordisk DKK 1.5B 28M Jun/2026
Pacira USD 3.62M 77K Jun/2026
Perrigo USD 7.61B 373.8M Jun/2026
Pfizer USD 667M 4M Jun/2026
Supernus Pharmaceuticals USD 910K 278K Jun/2023
United Therapeutics USD 2.9M 200K Jun/2026
Xeris Pharmaceuticals USD 6.88M 269K Mar/2026